Dysregulated iron metabolism in polycythemia vera: etiology and consequences. Ginzburg YZ, Feola M, Zimran E, Varkonyi J, Ganz T, Hoffman R. Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy. Verstovsek S, Harrison CN, Kiladjian JJ, Miller C, Naim AB, Paranagama DC, et al. Southeast Asian J Trop Med Public Health. Comparison of hematocrit/hemoglobin ratios in subjects with alpha-thalassemia, with subjects having chronic kidney disease and normal subjects. Insiripong S, Supattarobol T, Jetsrisuparb A. Relationship between haemoglobin and haematocrit in the definition of anaemia. Quintó L, Aponte JJ, Menéndez C, Sacarlal J, Aide P, Espasa M, et al. Can hemoglobin-hematocrit relationship be used to assess hydration status? Cermin Dunia Kedokteran. Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis. Ronner L, Podoltsev N, Gotlib J, Heaney ML, Kuykendall AT, O’Connell C, et al. Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Landolfi R, Di Gennaro L, Barbui T, De Stefano V, Finazzi G, Marfisi R, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, et al. Cardiovascular events and intensity of treatment in polycythemia vera. Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al. A British Society for Haematology guideline. A guideline for the diagnosis and management of polycythaemia vera. McMullin MF, Harrison CN, Ali S, Cargo C, Chen F, Ewing J, et al. Laboratory investigation of myeloproliferative neoplasms (MPNs): recommendations of the Canadian MPN group. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Masked polycythemia vera (mPV): results of an international study. Secondary polycythemia and the risk of venous thromboembolism. Higher red blood cell distribution width might differentiate primary from secondary polycythemia: a pilot study.
Holik H, Krečak I, Gverić-Krečak V, Vučinić Ljubičić I, Coha B. Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia vera. Nguyen E, Harnois M, Busque L, Sirhan S, Assouline S, Chamaki I, et al.
Erythrocytosis in the general population: clinical characteristics and association with clonal hematopoiesis. Wouters HJCM, Mulder R, van Zeventer IA, Schuringa JJ, van der Klauw MM, van der Harst P, et al. Higher HHR may represent iron deficiency and a stronger clonal myeloproliferation in PV and could provide additional prognostic information to the classical risk assessment. Using the receiver operating curve analysis-defined cut-off points, higher HHR in PV was associated with a shorter time to thrombosis (hazard ratio-HR 5.20, p = 0.022) independently of high-risk disease status (HR 4.48, p = 0.034) and shorter overall survival (HR 6.69, p = 0.009) independently of leukocytosis (HR 4.48, P = 0.034) and the absence of aspirin use (HR 15.53, p < 0.001). Among PV patients, higher HHR correlated with splenomegaly, higher total leukocyte and absolute granulocyte counts, higher red blood cell counts, lower hemoglobin, higher red blood cell distribution width, lower mean corpuscular hemoglobin and lower ferritin levels, whereas in SP patients higher HHR correlated with older age, female sex and lower hemoglobin ( p < 0.050 for all analyses). Median HHR was higher in PV than in SP patients (3.131 vs. We retrospectively assessed HHR at the time of diagnosis in 107 PV and 40 secondary polycythemia (SP) patients from three community hospitals. The hematocrit to hemoglobin ratio (HHR) is frequently used in everyday practice to measure hemoconcentration however, clinical associations of HHR in the context of polycythemia vera (PV) have not been investigated so far.
0 kommentar(er)
